Navigation Links
The MDS foundation supports vidaza's recommendation for European approval
Date:10/27/2008

The Myelodysplastic Syndromes (MDS) Foundation supports the positive opinion from the European Union's Committee for Medicinal Products for Human Use (CHMP) recommending approval of VIDAZA (azacitidine) for specific types of MDS patients, including those with high-risk MDS, chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).

The CHMP positive opinion was based upon data from the AZA-001 trial, which found that VIDAZA nearly doubled the two-year survival rate for higher-risk MDS patients compared to conventional care regimens (CCR) with a mean survival of 24.5 months compared to 15 months for patients who received CCR.

"We are very encouraged by the CHMP's recommendation for marketing approval for VIDAZA," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "The MDS Foundation is committed to making sure that patients in need are aware of and have access to new treatments, like VIDAZA, that can help patients to live longer and allow them to have a better quality of life."

The AZA-001 trial also showed that, VIDAZA delays the progression of MDS to acute myeloid leukemia (AML). Roughly 30 percent of patient diagnosed with MDS will progress to AML. The delay in progression is especially significant because patients with MDS are typically over the age of 65. According to the National Institute of Health, in this patient group, the average 5-year survival rate after diagnosis with AML is only approximately four percent.

MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the function of blood cells; red blood cells, white blood cells or platelets. The incidence of MDS is underestimated.


'/>"/>

Contact: Kathy Heptinstall
kheptinstall@MDS-Foundation.org
800-637-0839
The Myelodysplastic Syndromes Foundation
Source:Eurekalert

Page: 1

Related biology news :

1. Meyskens honored with AACR-Prevent Cancer Foundation award
2. Parkinsons Disease Foundation announces award of $150,000
3. The Camille & Henry Dreyfus Foundation to host important symposium on chemistry and the environment
4. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
5. National Science Foundation grant expands UMCES oyster research
6. Dunn Foundation gives Rice $3M for collaborative research grants
7. National Science Foundation grants Clemson professors award to develop nanoprobes
8. Entertainment Software Association Foundation awards grant to FAS for immune attack
9. A major prize in the chemical sciences announced by the Camille and Henry Dreyfus Foundation
10. UT Knoxville wins 2 $3M National Science Foundation research and education grants
11. The MDS Foundation supports the FDAs decision to expand vidaza label to include survival data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology: